X4 Pharmaceuticals (XFOR) investor relations material

Corporate strategy and restructuring

• Underwent significant restructuring in August 2023, introducing a new management team from CTI BioPharma and reducing headcount by 50%.

• Raised $240 million in two rounds last year, ensuring cash runway through commercialization to the end of 2028.

• Current cash position stands at $233 million with 144.8 million fully diluted shares outstanding.

• Supported by blue-chip investors and led by a C-suite team with expertise in hematology and drug launches.

Lead asset and clinical development

• Lead drug, mavorixafor, is approved for WHIM syndrome in the U.S. and EU and is being developed for chronic neutropenia.

• Phase III 4WARD trial targets chronic neutropenia, aiming for enrollment completion by Q3 2024 and top-line data in 2027.

• Target population for chronic neutropenia is 15,000 U.S. patients with moderate to severe disease.

• 4WARD trial is double-blinded, placebo-controlled, with co-primary endpoints: reduction in annual infection rate and increase in ANC by at least 500 cells/μL.

• Enrollment expanded to 110 active sites, with enhanced patient referral and AI-driven identification tools.

Clinical data and unmet needs

• Mavorixafor shown to increase neutrophil counts as monotherapy and in combination with G-CSF, with a mean G-CSF dose reduction of 70%.

• Drug is well-tolerated, with manageable GI side effects and no new safety signals in ongoing trials.

• Oral administration is highly desired by physicians, addressing a key unmet need compared to injectable G-CSF.

• Proof-of-concept data from phase II and WHIM studies support efficacy and safety.